N

Nexstim Oyj
OMXH:NXTMH

Watchlist Manager
Nexstim Oyj
OMXH:NXTMH
Watchlist
Price: 5.08 EUR -1.55% Market Closed
Market Cap: 34.4m EUR
Have any thoughts about
Nexstim Oyj?
Write Note

Nexstim Oyj
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Nexstim Oyj
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
N
Nexstim Oyj
OMXH:NXTMH
Capital Expenditures
-€1.6m
CAGR 3-Years
-44%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
R
Revenio Group Oyj
OMXH:REG1V
Capital Expenditures
-€4.2m
CAGR 3-Years
-36%
CAGR 5-Years
-23%
CAGR 10-Years
-27%
M
Modulight Oyj
OMXH:MODU
Capital Expenditures
-€15.7m
CAGR 3-Years
-97%
CAGR 5-Years
-64%
CAGR 10-Years
N/A
B
Bioretec Oy
OMXH:BRETEC
Capital Expenditures
-€161.4k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
O
Optomed Oyj
OMXH:OPTOMED
Capital Expenditures
-€2.4m
CAGR 3-Years
-10%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
B
Biohit Oyj
OMXH:BIOBV
Capital Expenditures
-€348k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-2%
No Stocks Found

Nexstim Oyj
Glance View

Market Cap
34.4m EUR
Industry
Health Care

Nexstim Oyj engages in the provision of medical technology products. The company is headquartered in Helsinki, Etela-Suomen and currently employs 37 full-time employees. The company went IPO on 2014-11-14. The company is focused on improving rehabilitation for stroke patients through the use of noninvasive brain stimulation. Its offering comprises: a diagnostic tool for brain surgery planning, Navigated Brain Stimulation (NBS) System, which comprises navigated transcranial magnetic stimulation (nTMS) device for presurgical mapping (PSM) of the motor and speech cortices; and a device for stroke therapy called Navigated Brain Therapy (NBT) System, which focuses stimulation on targeted locations in the brain in order to enhance rehabilitation process. The NBT System targets upper limb motor disability and is under Phase III pivotal clinical trial study at rehabilitation sites in the United States. The Company’s systems are used in over 100 facilities in research, therapy and neurosurgical planning purposes. Nexstim Oyj has two subsidiaries: Nexstim Inc and Nexstim Germany GmbH.

NXTMH Intrinsic Value
4.42 EUR
Overvaluation 13%
Intrinsic Value
Price
N

See Also

What is Nexstim Oyj's Capital Expenditures?
Capital Expenditures
-1.6m EUR

Based on the financial report for Jun 30, 2024, Nexstim Oyj's Capital Expenditures amounts to -1.6m EUR.

What is Nexstim Oyj's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-16%

Over the last year, the Capital Expenditures growth was 0%. The average annual Capital Expenditures growth rates for Nexstim Oyj have been -44% over the past three years , -16% over the past five years .

Back to Top